Cargando…

Current approaches to incorporation of radium-223 in clinical practice

BACKGROUND: Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), oral hormonal therapies targeting the androgen receptor axis (e.g., enzalutamide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parker, Chris, Heidenreich, Axel, Nilsson, Sten, Shore, Neal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895600/ https://www.ncbi.nlm.nih.gov/pubmed/29298991 http://dx.doi.org/10.1038/s41391-017-0020-y

Ejemplares similares

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA
por: Sartor, Oliver, et al.
Publicado: (2016)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
por: Heidenreich, Axel, et al.
Publicado: (2019)

Radium 223 dichloride for prostate cancer treatment
por: Deshayes, Emmanuel, et al.
Publicado: (2017)

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
por: Nilsson, Sten
Publicado: (2016)

Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
por: Heidegger, Isabel, et al.
Publicado: (2018)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Imaging and dosimetry for radium-223: the potential for personalized treatment
por: Flux, Glenn D
Publicado: (2017)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Radium-223 and concomitant therapies: prospects and prudence
por: Yeku, Oladapo, et al.
Publicado: (2016)

Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation
por: Hosono, Makoto, et al.
Publicado: (2018)

Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223
por: Hijab, Adham, et al.
Publicado: (2021)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
por: Mukherji, Deborah, et al.
Publicado: (2014)

Clinical aspects of mCRPC management in patients treated with radium-223
por: Rizzini, Elisa Lodi, et al.
Publicado: (2020)

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
por: Shore, Neal, et al.
Publicado: (2020)

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
por: Nilsson, S., et al.
Publicado: (2016)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Patient selection and treatment response assessment in radium-223 therapy
por: Kay, M, et al.
Publicado: (2015)

Radium-223 Treatment in mCRPC Patient with Polycythemia Vera
por: de Angelis, Cristina, et al.
Publicado: (2021)

Ocular complications with the use of radium-223: a case series
por: Bloom, Julie R., et al.
Publicado: (2022)

Radium-223 and bone metastatic disease: still more to learn
por: Sartor, Oliver
Publicado: (2023)

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
por: van der Doelen, Maarten J., et al.
Publicado: (2021)

Analysis of Unusual Adverse Effects After Radium-223 Dichloride  Administration
por: Frantellizzi, Viviana, et al.
Publicado: (2020)

Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227
por: Anderson, Peter M., et al.
Publicado: (2022)

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer
por: O’Sullivan, Joe M., et al.
Publicado: (2022)

Radium-223 Chloride: A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma
por: Pinto, Álvaro, et al.
Publicado: (2012)

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
por: Higano, Celestia S., et al.
Publicado: (2023)

Real-Time Scintigraphic Assessment of Intravenous Radium-223 Administration for Quality Control
por: Wright, Chadwick L., et al.
Publicado: (2015)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
por: van der Zande, Kim, et al.
Publicado: (2021)

Analysis of hematological parameters as prognostic markers for toxicity and survival of (223)Radium treatment
por: Leisser, Asha, et al.
Publicado: (2018)

Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
por: Aprile, Carlo, et al.
Publicado: (2016)

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation
por: Nguyen, Nghi C., et al.
Publicado: (2016)

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223
por: Sartor, O., et al.
Publicado: (2017)

Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy
por: Wenter, Vera, et al.
Publicado: (2017)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: Vidal, Monica, et al.
Publicado: (2020)

An agent-based model of prostate Cancer bone metastasis progression and response to Radium223
por: Casarin, Stefano, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qqkvn46domi30jkq1hq9hqeoef